Expedition Therapeutics raises $115.0M Series B (United States, Aug 2026)

Expedition secures $115 million to tackle COPD inflammation - Longevity.Technology

Expedition Therapeutics is a biotechnology company focused on developing innovative therapies for chronic obstructive pulmonary disease (COPD). The company is notable for its lead therapy, EXPD-101, which targets inflammation in the lungs, aiming to intervene earlier in the disease process rather than just alleviating symptoms. The recent $115 million Series B financing will support the launch of a global Phase 2 clinical trial for this treatment.

Expedition secures $115 million to tackle COPD inflammation  Longevity.Technology